Who
Tomas J. Heyman
Director
Company insider
Files Form 4 as: Director, Legend Biotech; Director, Exelixis; Director, Akero Therapeutics; Director, OptiNose; Director, Xilio Therapeutics; Director, Invivyd.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.6M
- Companies
- 6
- Companies where not an officer
- 6
- First trade
- 9 Jun 2020
- Last trade
- 24 Sep 2026
- Last filed
- 28 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 28 Sep 2026 | LEGN Legend BiotechBiotechnology | SEC FORM 4 Code A | —20,986 at $0.00 | filing |
| 24 Sep 2026filed 28 Sep 2026 | LEGN Legend BiotechBiotechnology | SEC FORM 4 Code A | —20,986 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 27 May 2026filed 29 May 2026 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —8,367 at $0.00 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —26,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —13,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —9,398 | filing |
| 3 Jun 2025filed 5 Jun 2025 | Akero Therapeutics | SEC FORM 4 Code A | —9,398 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —9,812 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | EXEL ExelixisBiotechnology | SEC FORM 4 Sold | $201K4,544 at $44.29 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —5,000 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —3,566 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —2,133 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —962 | filing |
| 21 May 2025filed 21 May 2025 | OptiNoseoption or derivative | SEC FORM 4 Code D | —1,925 | filing |
| 8 Jun 2024filed 11 Jun 2024 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | OptiNoseoption or derivative | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | EXEL ExelixisBiotechnology | SEC FORM 4 Code A | —18,838 at $0.00 | filing |
News
Citizens Jmp Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) StockEXEL · tickerreport.com · 21 Oct 2026Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law FirmEXEL · prnewswire.com · 13 Oct 2026
0 headlines in the last 90 days name Tomas J. Heyman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.